Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001213900-22-074269
Filing Date
2022-11-21
Accepted
2022-11-21 17:01:10
Documents
7
Period of Report
2022-12-08

Document Format Files

Seq Description Document Type Size
1 PROCY STATEMENT def14a1122_actiniumpharma.htm DEF 14A 1594917
2 GRAPHIC tactinium_logo.jpg GRAPHIC 134661
3 GRAPHIC tflowchart_001.jpg GRAPHIC 414177
4 GRAPHIC tlinechart_001.jpg GRAPHIC 227980
5 GRAPHIC tproxy_001.jpg GRAPHIC 1026977
6 GRAPHIC tproxy_002.jpg GRAPHIC 1352507
7 GRAPHIC tsandesh_sig.jpg GRAPHIC 15747
  Complete submission text file 0001213900-22-074269.txt   5966093
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36374 | Film No.: 221406557
SIC: 2834 Pharmaceutical Preparations